We are thankful to Sumaira Hussain from the Centre for Clinical Epidemiology and Biostatistics (CCEB), School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle (UoN), New South Wales (NSW), Australia, and Tabassum Rahman from Social Research Centre, Victoria, Australia, for their valuable inputs and for improving the language quality of the article. The American Society of Tropical Medicine and Hygiene (ASTMH) assisted with publication expenses.
Hasnain MG, Shomik MS, Ghosh P, Rashid MO, Hossain MS, Hamano S, Mondal D, 2016. Case report: post-kala-azar dermal leishmaniasis without previous history of visceral leishmaniasis. Am J Trop Hyg 95: 1383–1385.
WHO, 2012. Post Kala-azar Dermal Leishmaniasis: A Manual for Case Management and Control [Internet]. A report of a WHO consultative meeting, Kolkata, India, July 2–3 2012. Available at: http://apps.who.int/iris/bitstream/10665/78608/1/9789241505215_eng.pdf Accessed July 16, 2016.
Mondal D, Hamano S, Hasnain MG, Stocker AR, 2014. Challenges for management of post kala-azar dermal leishmaniasis and future directions. Res Rep Trop Med 5: 105–111.
Molina R, Ghosh D, Carrillo E, Monnerat S, Bern C, Mondal D, Alvar J, 2017. Infectivity of post-kala-azar dermal leishmaniasis patients to sand flies: revisiting a proof of concept in the context of the kala-azar elimination program in the Indian subcontinent. Clin Infect Dis 65: 150–153.
Mondal D, Nasrin KN, Huda MM, Kabir M, Hossain MS, Kroeger A, Thomas T, Haque R, 2010. Enhanced case detection and improved diagnosis of PKDL in a kala-azar endemic areas in Bangladesh. PLoS Negl Trop Dis 4: e832.
National guideline for kala-azar case management, 2015. Kala-azar Elimination Program. Communicable Disease Control. Disease control unit. Directorate general health services. Ministry of health and family welfare. Bangladesh: Government of Bangladesh.
Ramesh V, Ansari NA, Jain RK, Salotra P, 2007. Oral miltefosine in the treatment of post-kala-azar dermal Leishmaniasis. Clin Exp Dermatol 33: 103–104.
Ramesh V, Singh R, Avishek K, Verma A, Deep DK, Verma S, Salotra P, 2015. Decline in clinical efficacy of oral miltefosine in treatment of post kala-azar dermal leishmaniasis (PKDL) in India. PLoS Negl Trop Dis 9: e0004093.
Hasnain MG, Basher A, Nath P, Ghosh P, Hossain F, Hossain MS, Mondal D, 2016. Polymerase chain reaction in the diagnosis of visceral leishmaniasis recurrence in the setting of negative splenic smears. Am J Trop Hyg 94: 99–101.
Subhashree AR, Parameaswari PJ, Shanthi B, Revathy C, Parijatham BO, 2012. The reference intervals for the haematological parameters in healthy adult population of Chennai, southern India. J Clin Diagn Res 6: 1675–1680.
Diana Nicoll C, 2007. Appendix: therapeutic drug monitoring and laboratory reference ranges. Stephen JM, Maxine AP, eds. Current Medical Diagnosis and Treatment, 46th edition. Columbus, OH: McGraw Hill, 1767–1775.
Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ, 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 46: 828–833.